Bev-ICG

Phase 1Small molecule

IInstitute of Automation, Chinese Academy of Sciences

Bev-ICG is one of 7 small molecule programs targeting Gastrointestinal. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastrointestinalRecruiting

GastrointestinalPhase 1

Recruiting

Competition

Competitive Landscape

18 competitors in Gastrointestinal

#DrugCompanyPhaseTrials

Movantik

AAveritas Pharma, Inc.

Phase 3

1 2

Cytalux

OOn Target Laboratories, LLC

Phase 3

1 3

Octreotide

Johnson & Johnson

Preclinical

1 4

Bev-ICG

IInstitute of Automation, Chinese Academy of Sciences

Phase 1

1 5

Mosapride Citrate

IlDong Pharmaceutical Co Ltd

Preclinical

1 6

Buscopan

Boehringer Ingelheim

Preclinical

1 7

Dachengqi Decoction

XXinhua Hospital, Shanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastrointestinal1 trial

Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract

Recruiting·IInstitute of Automation, Chinese Academy of Sciences·Phase 1·NCT06430372·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bev-ICG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bev-ICG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bev-ICG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Automation, Chinese Academy of Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IInstitute of Automation, Chinese Academy of Sciences

Bev-ICG

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastrointestinal1 trial

References

Drug Info

Quick Facts

Related News